Pricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Return on equity (%)

ReproCELL Incorporated【JP:4978】

Market cap
¥16B
P/E ratio
-27.8x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndReturn on equity (%) (Million JPY)YoY (%)
Mar 31, 20251.2-397.50%
Mar 31, 2024-0.4-90.29%
Mar 31, 2023-4.1-54.73%
Mar 31, 2022-9.1-35.87%
Mar 31, 2021-14.2-8.33%
Mar 31, 2020-15.5+71.43%
Mar 31, 2019-9-71.69%
Mar 31, 2018-31.9+156.02%
Mar 31, 2017-12.5-54.41%
Mar 31, 2016-27.3+271.33%
Mar 31, 2015-7.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)